NCT00686582View on ClinicalTrials.gov

An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees

PHASE2CompletedINTERVENTIONAL
Enrollment

304

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

June 30, 2009

Conditions
Smallpox
Interventions
BIOLOGICAL

IMVAMUNE

1x 10E8\_TCID50

BIOLOGICAL

IMVAMUNE

1x 10E8\_TCID50

PROCEDURE

Blood Draw Only

Trial Locations (1)

80636

Harrison Clinical Research Deutschland GmbH, München

Sponsors

Lead Sponsor

Bavarian Nordic
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Bavarian Nordic

INDUSTRY

NCT00686582 - An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees | Biotech Hunter | Biotech Hunter